Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DILfrequency: Adaptive Study of IL-2 Dose Frequency in T1D
NCT02265809Phase 2Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Oct 2014
- Primary completion
- May 2016
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in type 1 diabetes mellitus (T1D), sponsored by Cambridge University Hospitals NHS Foundation Trust. Started Oct 2014; status: completed.
02
Drugs
aldesleukin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02265809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02265809.